An injection to treat forehead wrinkles is set to rival Allergan plc’s Botox after U.S. regulators approved Evolus Inc.’s cheaper treatment, sending the Newport Beach, Calif.-based company’s shares up about 5 percent.

The U.S. Food and Drug Administration approved Medicines Co.’s antibacterial drug for patients with complicated urinary tract infections (cUTI).

Dupilumab, Regeneron/Sanofi Dupilumab is the first systemic therapy to demonstrate positive Phase III results in patients with moderate-to-severe atopic dermatitis. The serious, chronic inflammatory skin disease is marked by widespread rash, itching and associated psychosocial comorbidities. Dupilumab inhibits interleukin-4 and interleukin-13, which are small anti-inflammatory proteins secreted by cells that are thought to play a […]

FDA gave Tecentriq accelerated approval to treat specific types of advanced bladder cancer.

The VENTANA PD-L1 (SP142) Assay was approved as a complementary diagnostic for Tecentriq immunotherapy.

Telesta Therapeutics announced that the company will not start another Phase III clinical trial on its own of MCNA, a drug for high-risk, non-muscle invasive bladder cancer patients.

Japan’s Astellas is seeking more deals to refill its drug pipeline as the pharmaceutical company created through a merger 10 years ago explores opportunities in both established and new therapy areas.   “We’re never satisfied with what we have, so we are looking at strategies to augment the portfolio. Nothing is off the table for […]